Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis
Section snippets
Acknowledgements
This work was supported by the Medical Faculty of the University of Göttingen, Germany (junior research group; R. D.), the Gemeinnützige Hertie Foundation, and by a research grant from Bayer Vital GmbH.
References (38)
- et al.
Serum neurone-specific enolase concentrations in patients with neurological disorders
Clin. Chim. Acta
(1994) - et al.
Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein
Biochem. Biophys. Res. Commun.
(1984) - et al.
S100B as a predictor of size and outcome of stroke after cardiac surgery
Ann. Thorac. Surg.
(2001) - et al.
Plasma S100beta and NSE levels and progression in multiple sclerosis
J. Neurol. Sci.
(2007) - et al.
Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis
Neurosci. Lett.
(2004) - et al.
Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis
J. Neurol. Sci.
(2003) - et al.
Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum
Neurosci. Lett.
(2003) - et al.
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization
Neurosci. Lett.
(2000) - et al.
The distribution of tau in the mammalian central nervous system
J. Cell Biol.
(1985) - et al.
Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis
Mult. Scler.
(2005)
The 14-3-3 protein in multiple sclerosis: a marker of disease severity
Mult. Scler.
(2004)
14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis
J. Neurol.
(2002)
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study
Brain
(1998)
Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury
Neurology
(2003)
Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis
Mult. Scler.
(2006)
Core biological marker candidates of Alzheimer's disease—perspectives for diagnosis, prediction of outcome and reflection of biological activity
J. Neural. Transm.
(2004)
Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study
Stroke
(2006)
Amyloid beta-peptide and the dementia of Parkinson's disease
Mov. Disord.
(1996)
Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis
Acta Neurol. Scand.
(2002)
Cited by (61)
Neutrophil activity in serum as a biomarker for multiple sclerosis
2023, Multiple Sclerosis and Related DisordersBiochemical biomarkers for multiple sclerosis
2023, Clinica Chimica ActaCerebrospinal Tau levels as a predictor of early disability in multiple sclerosis
2021, Multiple Sclerosis and Related DisordersSerum and saliva total tau protein as a marker for relapsing-remitting multiple sclerosis
2020, Medical HypothesesCitation Excerpt :They showed that serum tau protein level was higher in MS patients than control individuals. However, in other studies, there was no significant difference in CSF tau protein between the two groups [2,6,9,19,20]. Serum total tau protein in our study was in contrast of the above reports in MS women.
Role of amyloid-β CSF levels in cognitive deficit in MS
2015, Clinica Chimica ActaEmerging imaging and liquid biomarkers in multiple sclerosis
2023, European Journal of Immunology
Copyright © 2008 Elsevier Ireland Ltd. All rights reserved.